Italia markets close in 5 hours 46 minutes

Blueprint Medicines Corporation (0HOJ.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
59,24+8,29 (+16,27%)
Al 04:38PM BST. Mercato aperto.
Schermo intero
Chiusura precedente50,95
Aperto59,24
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno59,24 - 59,24
Intervallo di 52 settimane59,24 - 59,24
Volume0
Media VolumeN/D
Capitalizzazione28,735M
Beta (5 anni mensile)0,94
Rapporto PE (ttm)N/D
EPS (ttm)-11,06
Prossima data utili26 ott 2022 - 31 ott 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

    Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based m

  • GlobeNewswire

    Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

    -- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China -- -- Blueprint Medicines to receive $25 million upfront payment, up to $590 million in potential future milestone payments, and royalties -- CAMBRIDGE, Mass., SHANGHAI and SAN FRANCISCO, Nov. 09, 2021 (